Abeona Therapeutics, Inc. (ABEO)

Abeona Therapeutics' stock experienced a jump in November 2025 due to strong third-quarter earnings and positive updates on ZEVASKYN. The commercial launch of ZEVASKYN was delayed to the fourth quarter of 2025 due to the need for optimization of a rapid sterility release assay required by the FDA. In late January and early February 2026, several independent directors and executives engaged in stock sales. The stock price as of February 2, 2026, was $5.17, representing a 6.00% decline over the preceding year.

The provided information does not explicitly detail demand seasonality for Abeona Therapeutics' products and services. Given that the company focuses on gene and cell therapies for rare diseases, significant seasonality is unlikely. The company has noted an expectation for a "gradual ramp-up" in ZEVASKYN patient treatments.

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on gene and cell therapies for rare diseases, operating in the Biotechnology industry. Their flagship product, ZEVASKYN, is a gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Abeona also develops AAV-based gene therapies for ophthalmic diseases and utilizes its AIM vector platform. The company's revenue has historically been driven by licensing agreements and non-recurring events.

Abeona Therapeutics Inc. has its principal executive offices in New York City and a cGMP manufacturing facility in Cleveland, Ohio, for ZEVASKYN production. The company plans to expand its laboratory facilities in Midtown Cleveland. Broader operational mentions include the United States, Singapore, and Israel.

Abeona Therapeutics has seen positive developments in its brand reputation, driven by the FDA approval of ZEVASKYN in April 2025. Analyst ratings have generally been positive, with Wall Street analysts rating ABEO as "Very Bullish" on average. The company's strong Q3 2025 earnings and positive updates on ZEVASKYN's progress have also contributed positively to its reputation. The establishment of a permanent J-code for ZEVASKYN by CMS further underscores market acceptance and access.

Abeona Therapeutics Inc. has a mixed ownership structure. Approximately 56.60% of the company's stock is owned by institutional investors, 5.28% by insiders, and 38.12% by public companies and individual investors. Major institutional owners include Nantahala Capital Management, LLC, BlackRock, Inc., Adage Capital Partners Gp, L.l.c., Vanguard Group Inc, Suvretta Capital Management, Llc, AIGH Capital Management LLC, and Vivo Capital, LLC. Significant individual and insider owners include Sco Capital Partners LLC and Steven H. Rouhandeh.